Amicus Therapeutics, Inc. (FOLD) Presents Patient Screening Profiles From Phase 3 Fabry Study  
2/13/2012 10:16:53 AM

CRANBURY, N.J., Feb. 13, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, recently presented updated information on the number and type of patients screened for and enrolled in the global Phase 3 registration study (Study 011) of the investigational pharmacological chaperone migalastat HCl, being studied as a potential monotherapy for Fabry disease.